CommentWHO recommendations on shorter treatment of multidrug-resistant tuberculosis
References (14)
- et al.
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Lancet Infect Dis
(2016) - et al.
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Lancet Infect Dis
(2016) Global Tuberculosis Report 2015
Multidrug-resistant tuberculosis (MDR-TB)
The end TB strategy
- et al.
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
Eur Respir J
(2013) - et al.
Classification of antituberculosis drugs: a new proposal based on the most recent evidence
Eur Respir J
(2015)
Cited by (49)
Outcomes and adherence of shorter MDR TB regimen in patients with multidrug resistant tuberculosis
2023, Indian Journal of TuberculosisCitation Excerpt :In 2016, WHO guidelines conditionally recommended a shorter 9–12-month MDR-TB regimen for patients meeting specific criteria, based on results of a systematic review and individual patient data meta-analysis.3,4 However, uncertainty remains about the regimen's effectiveness in the presence of resistance to constituent drugs, including fluoroquinolones, ethambutol, pyrazinamide and prothionamide.5–9 To study adherence and treatment outcome of shorter MDR TB regimen in patients with MDR-TB.
Simultaneous determination of the potent anti-tuberculosis regimen—Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC–MS/MS method coupled with 96-well format plate
2019, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :Some researches have uncovered the synergism activity among CFZ and other anti-TB drugs, especially co-administrated with EMB and PZA [19,20]. The treatment guidelines for drug-resistant TB of WHO in 2016 highlighted the capacity of CFZ and the CFZ-contained regimen (including PZA, EMB, PTO, CFZ, kanamycin acid and isoniazid) for MDR-TB patients for the shorter treatment course, low cost and accessibility [18]. One most effective regimen containing these four compounds for MDR-TB patients with a minimum period of nine-month treatment has been validated for naive MDR-TB patients by a clinical trial in Bangladesh from 1997 to 2007 [21].
Would pan-tuberculosis treatment regimens be cost-effective?
2018, The Lancet Respiratory MedicineVicinal Diaryl Pyrazole: A Therapeutically Potential Molecular Scaffold
2018, Vicinal Diaryl Substituted Heterocycles: A Gold Mine for the Discovery of Novel Therapeutic AgentsTuberculosis treatment for children: An update
2018, Anales de PediatriaRole of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis
2017, International Journal of Antimicrobial Agents